Taste, taste, and more taste. BI brings you inside a day at Vibecon.

Replimune gets third chance at US approval for skin cancer drug Replimune said on Friday it plans to apply a third time for approval of its experimental skin cancer drug in the coming days after ...

Model choice actually did more work than the tools did ...

REPL shares soared 85.7% after FDA alignment on RP1 plus Opdivo BLA resubmission plans. Replimune plans to resubmit the BLA in the coming days. The FDA intends to prioritize review. The RP1 plus ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Replimune Group, Inc.'s RP1 has failed at the FDA twice, but Makary's resignation keeps a resubmission possible. REPL's cash runway stands at under a year; workforce cuts and RP1 discontinuation are ...

This project is a proof-of-concept that runs a JavaScript engine inside a web browser by compiling it to WebAssembly. The engine is Goja — a pure-Go implementation of ECMAScript 5.1 — and the ...

Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...

The JavaScript innovation train is really picking up momentum lately, driven—as always—by the creativity of the JavaScript developer community. The emerging local-first SQL datastores crystalize ideas ...

Shares of Replimune Group, Inc. (REPL Quick Quote REPL - Free Report) have gained 2.7% over the past four weeks to close the last trading session at $7.16, but there could still be a solid upside left ...